SUBSCRIBE TO OUR RSS
INITIAL PUBLIC OFFERINGS
An Open Window
Life Sciences companies that have gone public since August 2009.
The Burrill Report
April 08, 2010
[Please login to post comments]
A Hammer in Search of a Nail
DEA grows impatient with the pace at which the FDA addresses opioid abuse.
Actavis Buys Warner Chilcott
Combination will create a tax-advantaged global specialty pharma.
Gates Foundation Helps Repurpose Exubera Technology
Monash Institute of Pharmaceutical Sciences receives more than $1 million for drug delivery development.
Industry Advocates Ally to Lobby for Tax Reforms
New group draws together BIO, AdvaMed, and others seeking tax code changes.
Elan Strikes More Deals, Rejects Sweetened Royalty Pharma Bid
Pharma moves to acquire two companies, spin out a program, and issue debt.
What Wall Street's Watching at ASCO
Podcast: May 28, 2013
Stem Cell Policy Group Folds Tent
Coalition for the Advancement of Medical Research transfers mission and assets to Alliance for Regenerative Medicine.
GSK and BARDA Collaborate to Develop New Antibiotics
The $200M deal seeks to create a pipeline of new drugs.
Pfizer Drug Fails Three Late-stage Trials
The weekly round-up of failed trials, missed targets, and other business mishaps.
Obama Administration Offers $1 Billion for Healthcare Innovation
HHS awards designed to transform delivery and payment systems.
Copyright 2013 Burrill & Company.
FACEBOOK AND TWITTER